NETRIS Pharma's NP137 Shows Promising Results in Pancreatic Cancer Phase 1b Trial Published in Nature

Key Takeaways

• NP137 combined with mFOLFIRINOX achieved 16.43 months median overall survival and 10.85 months progression-free survival in locally advanced pancreatic cancer
• 23% of patients became eligible for surgery after treatment, potentially offering new hope for inoperable pancreatic cancer cases
• First-in-class anti-netrin-1 monoclonal antibody may overcome chemoresistance, with results published in prestigious Nature journal

---

Breakthrough Results for Difficult-to-Treat Cancer

NETRIS Pharma announced that Nature has published positive Phase 1b results for NP137, the company’s first-in-class anti-netrin-1 monoclonal antibody, in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). The LAPNET-01 study demonstrates that netrin-1 blockade may overcome and prevent chemoresistance in one of oncology’s most challenging cancers.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Trial Outcomes Exceed Expectations

Patients with locally advanced pancreatic cancer treated with NP137 in combination with mFOLFIRINOX chemotherapy achieved significant clinical milestones. The median overall survival reached 16.43 months, while median progression-free survival extended to 10.85 months. Perhaps most notably, 23% of patients achieved conversion-to-surgery rates, meaning nearly a quarter of previously inoperable patients became surgical candidates.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Novel Mechanism Targets Chemoresistance

NP137 represents a novel approach to pancreatic cancer treatment by targeting netrin-1, a protein that plays a crucial role in cancer cell survival and chemotherapy resistance. This mechanism of action differentiates NP137 from existing treatments and offers potential benefits for patients who typically have limited therapeutic options.

Pancreatic ductal adenocarcinoma remains one of the most aggressive cancers, with five-year survival rates below 10%. Locally advanced cases are particularly challenging, as tumors are typically unresectable at diagnosis due to involvement with major blood vessels.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market and Clinical Implications

The publication in Nature, one of the world’s most prestigious scientific journals, validates the clinical potential of anti-netrin-1 therapy. These Phase 1b results support advancing NP137 into later-stage clinical development, potentially offering new hope for pancreatic cancer patients who currently face limited treatment options.

The combination’s ability to convert inoperable tumors to surgical candidates represents a significant clinical advancement, as surgery remains the only potentially curative treatment for pancreatic cancer.

---

Frequently Asked Questions

What does this mean for pancreatic cancer patients?

NP137 offers potential new hope by extending survival and making some inoperable tumors eligible for surgery. However, the drug is still in clinical trials and not yet available as a standard treatment option.

When will NP137 be available to patients?

NP137 is currently in Phase 1b trials. The drug will need to complete Phase 2 and Phase 3 trials before seeking regulatory approval, which typically takes several years.

How does NP137 compare to existing pancreatic cancer treatments?

NP137 targets a novel pathway (netrin-1) that may overcome chemoresistance, potentially offering benefits where current treatments fail. The 23% surgery conversion rate and 16.43-month survival suggest promising activity in this difficult-to-treat cancer.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Breast Cancer Statistics Worldwide: What the Data Shows
• Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses